Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

ble non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding the potential benefits and potential development of our product candidates and statements regarding our expected financial results and expected cash requirements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product, the risk that our cash resources are insufficient to fund our planned activities for the time period expected and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Donald Spector , a renowned ... 8,823,512 for a Wearable Biosensor, which will issue today, ... this field.  Mr. Spector holds some of the earliest ... made today by New York College of Health Professions, ... of world-class intellectual properties.  New York College noted that ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... AMN Healthcare Services, Inc. (NYSE: AHS ), the largest ... quarterly conference call to discuss third quarter results on Thursday, ... also expects to issue an earnings news release on Thursday, ... 4:00 p.m. Eastern Time. , A live webcast of the ...
... CPhI Worldwide and connected events - the global pharma ingredients and ... - 15 October for its 20th staging. , The co-located ... technology events are joined for 2009 under the Where Pharma ... The new platform markedly reflects the notable convergence of the pharma ...
Cached Medicine Technology:AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
(Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
(Date:9/2/2014)... apnea, tonsillectomies, hearing loss, head and neck cancers ... Orlando, FL, September 21-24, at the 2014 Annual ... of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF), the ... and neck physicians in the world. , Abstracts ... today, and are available online at http://oto.sagepub.com/content/151/1_suppl ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... of Experimental Biology and Medicine that ... biology and medicine of microphysiological systems" and describes ... Systems Program directed by the National Center for ... of Health (NIH) and funded in part by ... Projects Agency (DARPA) and the Food and Drug ...
Breaking Medicine News(10 mins):Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Microphysiological systems will revolutionize experimental biology and medicine 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 3
... , , , ... Sustained reduction of mitral regurgitation following mitral valve repair ... (DMR) or functional mitral regurgitation (FMR) led to heart function ... initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair ...
... , , , , ... over 2,000 motorcycle riders and enthusiasts will gather at Wisconsin Harley-Davidson ... "Ridin, to a Cure" fund raiser for breast cancer research in ... raise in excess of $300,000 over the weekend. The ride has ...
... , , One of Nation,s Best ... The health care network operated by the Department of Veterans Affairs (VA) has ... by the American Association of Retired Persons (AARP). , , "Quality ... Affairs Eric K. Shinseki. "VA is proud to be recognized as a top ...
... CHELMSFORD, Mass., Sept. 22 Magellan Biosciences, Inc. (Magellan), ... Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. ... ESA,s HPLC-related products, HPLC clinical assays, the ESA Laboratories services ... Financial terms of the transaction were not disclosed. , ...
... VA Physical therapist-directed exercise counseling combined with ... and exercise capacity in people with type 2 ... exercise, according to a randomized clinical trial published ... , the scientific journal of the American Physical ...
... Mo. About 2 million Americans currently use cocaine ... to making it one of the most dangerous and ... cause severe biological and behavioral problems, is very difficult ... and Sandeep Pendyam, doctoral students in the Department of ...
Cached Medicine News:Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 2Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 3Health News:We Need Your Support - 'Ridin' to a Cure' Sept. 25 and 26 2Health News:VA's Health System Top Employer for AARP 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 3Health News:People with type 2 diabetes improved muscular strength 2Health News:Computer model shows changes in brain mechanisms for cocaine addicts 2
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
... A sophisticated research tool that allows ... area which is being stimulated. Besides it ... the examiner to switch between the pupil ... computer screen. This system is especially suited ...
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Medicine Products: